gemfibrozil has been researched along with lovastatin in 127 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (11.02) | 18.7374 |
| 1990's | 88 (69.29) | 18.2507 |
| 2000's | 16 (12.60) | 29.6817 |
| 2010's | 9 (7.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afonso, A; Burnett, DA; Clader, JW; Davis, HR; Huynh, T; Rosenblum, SB; Yumibe, N | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Eichinger, M; Feussner, G; Ziegler, R | 1 |
| McIntyre, TH; Shapiro, ML; Whitney, EJ; Wirebaugh, SR | 1 |
| Belzer, FO; D'Alessandro, AM; Kalayoglu, M; Knechtle, SJ; Pirsch, JD; Reed, A; Sollinger, HW | 1 |
| Barnett, MD; McKenney, JM; Proctor, JP; Wright, JT | 1 |
| Chucrallah, A; De Girolami, U; Federman, M; Freeman, R | 1 |
| Foo, WM; Lim, MC | 1 |
| Tikkanen, MJ; Tilly-Kiesi, M | 2 |
| Glueck, CJ; Lang, J; Oakes, N; Speirs, J; Tracy, T | 1 |
| D'Agostino, LC; D'Agostino, RB; Kannel, WB; Stepanians, MN | 1 |
| Neuman, HR; Neuman, J; Neuman, MP | 1 |
| Aguirre, C; Anglada, J; Anguita, M; Azanza, JR; Barcina, C; Fabiani, F; Plaza, L; Soriguer, F; Vallés, F | 1 |
| Batlouni, M; Bertolami, MC; Bismarck, ZF; Faludi, AA; Martinez, TL; Melo, RS; Pinto, LE | 1 |
| Bernardi, G; Gavelli, MS; Rossi, FG; Santini, G; Serra, T; Vitaliano, E | 1 |
| Colley, C; Lucas, LM; Magarian, GJ | 1 |
| Jensen, K | 1 |
| Helve, E; Ojala, JP; Tikkanen, MJ | 2 |
| D'Amico, G; Gentile, MG | 1 |
| Gross, KF; London, SF; Ringel, SP | 1 |
| Garcia, RC; Nakandakare, E; Oliveira, HC; Quintão, EC; Rocha, JC; Sperotto, G | 1 |
| Eisenberg, JM; Glick, H; Jacobson, TA; Kinosian, B; Koffer, H; Schulman, KA; Willian, MK | 1 |
| Shapiro, DR; Walker, JF | 1 |
| Goldberg, R; La Belle, P; Ronca, P; Zupkis, R | 1 |
| Grundy, SM; Vega, GL | 5 |
| Connor, WE | 1 |
| Bentivoglio, M; Berioli, S; Conti, R; Corea, L; Osanna, RA; Savino, K; Zollino, L | 1 |
| Larson, KK; Marais, GE | 1 |
| Carlson, LA | 1 |
| Glueck, CJ; Speirs, J; Tracy, T | 1 |
| Gross, TP; Pierce, LR; Wysowski, DK | 1 |
| Kogan, AD; Orenstein, S | 1 |
| Bacon, S; Illingworth, DR | 1 |
| Bocanegra, TS; Cook, T; Tikkanen, MJ; Walker, JF | 1 |
| Garg, A; Grundy, SM | 1 |
| Fishman, AB; Goldman, JA; Johnson, RJ; Lee, JE | 1 |
| Helve, E; Jäättelä, A; Kaarsalo, E; Lehtonen, A; Malbecq, W; Oksa, H; Pääkkönen, P; Salmi, J; Tikkanen, MJ; Veharanta, T | 1 |
| East, C; Grundy, SM; Vega, GL | 1 |
| Mölgaard, J; Olsson, AG | 1 |
| Hunninghake, DB | 1 |
| Bilheimer, DW; East, C; Grundy, SM | 1 |
| Nikkilä, EA; Tikkanen, MJ | 1 |
| Perry, RS | 1 |
| Maxwell, RE; Nawrocki, JW; Uhlendorf, PD | 1 |
| Tobert, JA | 2 |
| Ahmad, S | 1 |
| Benson, VV; Borok, GM; Dudl, RJ; Epstein, A; Epstein, RS; Heys, JF; Menzin, J; Oster, G; Quinn, V | 1 |
| Alaupovic, P; Dudley, VS; Knight-Gibson, C; Lane, DM; Laughlin, LO | 1 |
| Chamone, D; da Luz, P; Mansur, AP; Maranhão, R; Pileggi, F; Ramires, JA; Solimene, MC | 1 |
| Castro Cabezas, M; De Bruin, TW; Erkelens, DW; Kock, LA | 1 |
| Bredie, SJ; de Bruin, TW; Demacker, PN; Kastelein, JJ; Stalenhoef, AF | 1 |
| Johansson, J; Lithell, H; Ohrvall, M; Vessby, B | 1 |
| Bays, H; Lansing, AM | 1 |
| de Alava, E; Lozano, MD; Pardo-Mindán, FJ; Sola, JJ | 1 |
| Lu, ZL | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Ciafone, R; Galen, M; Knoll, RW | 1 |
| Ooi, TC; Simo, IE; Yakichuk, JA | 1 |
| Baigts, F; Devulder, B; Lecerf, JM; Luc, G | 1 |
| Cramb, R; Head, A; Jakeman, PM; Kendall, MJ; Maxwell, S | 1 |
| Rosenson, RS | 2 |
| Hunninghake, DB; Knutson, KR; Kubo, SH; Olivari, MT; Peters, JR | 1 |
| Abdul-Ghaffar, NU; el-Sonbaty, MR | 1 |
| Baigts, F; Bruckert, E; De Gennes, JL; Malbecq, W | 1 |
| Illingworth, R | 1 |
| Boissonnat, P; de Lorgeril, M; Dureau, G; Monjaud, I; Salen, P | 1 |
| Aranda, JL; del Palacio, A; Jover, E; Nogués, X; Rubiés-Prat, J | 1 |
| Coulter, DM | 1 |
| Chiari, A; Ghiselli, G; Giorgini, L; Lovisolo, PP; Musanti, R; Pirillo, A | 1 |
| Bredie, SJ; de Bruin, TW; Kastelein, JJ; Knipscheer, HC; Stalenhoef, AF; Westerveld, HT | 1 |
| Akçiçek, F; Alev, M; Atabay, G; Basçi, A; Duman, S; Kürsad, S; Ok, E; Unsal, A | 1 |
| Glueck, CJ; Lang, JE; Wang, P | 1 |
| Aumont, MC; Seknadji, P | 1 |
| Bambauer, R; Müller, UA; Schiel, R | 1 |
| Du Buf-Vereijken, PW; Spooren, PF; van Doormaal, JJ; van Puijenbroek, EP | 1 |
| Autier, P; Muls, E; Van Gaal, L; Vansant, G | 1 |
| Haffner, SM | 1 |
| Barter, P; Clifton, P; Colquhoun, D; Hamilton-Craig, I; Nestel, P; Sikaris, K; Simons, L; Sullivan, D | 1 |
| Isley, W; Rajeshawari, M; Tal, A | 1 |
| Athyros, VG; Carina, MV; Didangelos, TP; Hatzikonstandinou, HA; Kontopoulos, AG; Kranitsas, DF; Papageorgiou, AA | 1 |
| Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M | 1 |
| Chamone, D; da Luz, PL; Mansur, AP; Pileggi, F; Ramires, JA; Solimene, MC; Spósito, AC | 1 |
| Adzet, T; Hernández, Y; Laguna, JC; Merlos, M; Ros, E; Vázquez, M; Zambón, D | 1 |
| Ballesta, AM; Casals, E; Ojuel, J; Rodriguez-Villar, C; Ros, E; Sanllehy, C; Zambón, D | 1 |
| Bergö, M; Bond, BC; Gribble, AD; Groot, PH; Havekes, LM; Hofker, MH; Pearce, NJ; Staels, B; van Vlijmen, BJ; Yates, JW | 1 |
| Sinzinger, H | 1 |
| Casals, E; Hernández, G; Laguna, JC; Rodriguez-Villar, C; Ros, E; Sanllehy, C; Sol, JM; Vázquez, M; Zambón, D | 1 |
| Fuh, MM; Hung, YJ; Jeng, C; Kuo, SW; Pei, D; Wu, DA | 1 |
| Haffner, SM; Rader, DJ | 1 |
| Frane, AM; Gantner, SE; Joyce, DM; Kersten, ME; Murdock, AK; Murdock, DK; Murdock, RW; Olson, KJ | 1 |
| Freeman, NJ; Landesman, KA; Stozek, M | 1 |
| Mendonça, CX; Mori, AV; Santos, CO | 1 |
| Black, DM | 1 |
| Harangi, M; Paragh, G | 1 |
| Backman, JT; Kivistö, KT; Kyrklund, C; Laitila, J; Neuvonen, M; Neuvonen, PJ | 1 |
| Sprecher, DL | 1 |
| Pearson, TA | 1 |
| Mikhailidis, DP; Milionis, HJ; Rizos, E | 1 |
| Platts, J | 1 |
| Bouzamondo, A; Corvol, JC; Hulot, JS; Lechat, P; Sanchez, P; Sirol, M | 1 |
| Barberá, G; Chacón, P; Hernández, C; Lecube, A; Lima, J; Simó, R | 1 |
| Boden, WE | 1 |
| Dellavalle, RP; Drake, AL; Freeman, SR; Graber, M; Heilig, LF; McNealy, K; Schilling, LM | 1 |
| Dimitri, E; Landry, P; Légaré, N; Tessier, S | 1 |
| Fan, J; Jiang, L; Kong, X; Li, Z; Wu, T; Yuan, H | 1 |
| Akai, S; Matsubara, A; Oda, S; Watanabe, K; Yokoi, T | 1 |
20 review(s) available for gemfibrozil and lovastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Hyperlipidemia and transplantation: etiologic factors and therapy.
Topics: Adrenal Cortex Hormones; Antihypertensive Agents; Coronary Disease; Diuretics; Gemfibrozil; Humans; Hyperlipidemias; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lipid Metabolism; Lipoprotein Lipase; Lovastatin; Postoperative Complications; Risk Factors | 1992 |
Gemfibrozil-induced myopathy.
Topics: Clofibrate; Drug Therapy, Combination; Gemfibrozil; Humans; Hypertriglyceridemia; Lovastatin; Male; Middle Aged; Muscular Diseases | 1991 |
Reducing high blood cholesterol level with drugs. Cost-effectiveness of pharmacologic management.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Colestipol; Cost-Benefit Analysis; Drug Therapy, Combination; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; Probucol; Sensitivity and Specificity | 1990 |
Contemporary recommendations for evaluating and treating hyperlipidemia.
Topics: Clofibrate; Dextrothyroxine; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lipoproteins; Lovastatin; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Phenotype; Probucol | 1986 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type IV; Hyperlipoproteinemias; Lactation; Lipoproteins; Lovastatin; Naphthalenes; Niacin; Pentanoic Acids; Pregnancy; Pregnancy Complications; Probucol; Tangier Disease; Triglycerides | 1984 |
[Secondary prevention after myocardial infarction; rôle of platelet antiaggregants and hypolipemic agents].
Topics: Anticholesteremic Agents; Aspirin; Coronary Disease; Cost-Benefit Analysis; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; Myocardial Infarction; Platelet Aggregation Inhibitors; Risk Factors; Simvastatin | 1996 |
Effect of statins on metabolism of apo-B-containing lipoproteins in hypertriglyceridemic men.
Topics: Apolipoproteins B; Cholesterol, LDL; Cholesterol, VLDL; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lovastatin; Male; Niacin | 1998 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
Role of fibrates in the management of hypertriglyceridemia.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Lovastatin; Male; Randomized Controlled Trials as Topic; Risk Factors | 1999 |
Statins in children: what do we know and what do we need to do?
Topics: Atorvastatin; Bezafibrate; Child; Child Welfare; Cost-Benefit Analysis; Drug Approval; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Pyridines; Pyrroles; Simvastatin | 2001 |
[The role of HDL in the prevention of cardiovascular events].
Topics: Anticholesteremic Agents; Arteriosclerosis; Aryldialkylphosphatase; Atorvastatin; Cholesterol, HDL; Esterases; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipid Peroxidation; Lovastatin; Phosphatidylcholine-Sterol O-Acyltransferase; Pyrroles; Simvastatin | 2001 |
Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Drug Combinations; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Myocardial Infarction; Niacin; Ultrasonography | 2000 |
Divergent approaches to the treatment of dyslipidemia with low levels of high-density lipoprotein cholesterol.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Drug Combinations; Ethanol; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Life Style; Lovastatin; Niacin | 2000 |
Smoking diminishes the beneficial effect of statins: observations from the landmark trials.
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Gemfibrozil; Humans; Lovastatin; Myocardial Ischemia; Pravastatin; Risk Factors; Simvastatin; Smoking | 2001 |
Differential effects of lipid-lowering therapies on stroke prevention: a meta-analysis of randomized trials.
Topics: Anticholesteremic Agents; Atorvastatin; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Myocardial Infarction; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Regression Analysis; Risk Assessment; Risk Factors; Simvastatin; Stroke; Treatment Failure; Treatment Outcome | 2003 |
Therapeutic implications of recent ATP III guidelines and the important role of combination therapy in total dyslipidemia management.
Topics: Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetic Angiopathies; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Metabolic Syndrome; Practice Guidelines as Topic | 2003 |
Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Gemfibrozil; Humans; Hypolipidemic Agents; Lipoproteins, LDL; Lovastatin; Risk Factors; Simvastatin | 2005 |
Statins, fibrates, and melanoma risk: a systematic review and meta-analysis.
Topics: Atorvastatin; Bezafibrate; Clofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Incidence; Lovastatin; Melanoma; Odds Ratio; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Reproducibility of Results; Simvastatin; Skin Neoplasms; United States | 2006 |
Lipid-lowering agents for nephrotic syndrome.
Topics: Adult; Child; Fatty Acids, Monounsaturated; Fluvastatin; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lovastatin; Nephrotic Syndrome; Randomized Controlled Trials as Topic; Simvastatin | 2013 |
42 trial(s) available for gemfibrozil and lovastatin
| Article | Year |
|---|---|
The influence of simvastatin alone or in combination with gemfibrozil on plasma lipids and lipoproteins in patients with type III hyperlipoproteinemia.
Topics: Adult; Apolipoprotein E2; Apolipoproteins E; Cholesterol; Cholesterol, LDL; Combined Modality Therapy; Dietary Fats; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type III; Hyperlipoproteinemias; Lipids; Lipoproteins; Lipoproteins, VLDL; Lovastatin; Male; Simvastatin; Triglycerides | 1992 |
Comparison of gemfibrozil and lovastatin in patients with high low-density lipoprotein and low high-density lipoprotein cholesterol levels.
Topics: Cholesterol, Dietary; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged | 1992 |
A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Multivariate Analysis; Research Design; Triglycerides | 1992 |
Significant increase of high-density lipoprotein2-cholesterol under prolonged simvastatin treatment.
Topics: Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1991 |
A multicenter double-blind study comparing lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Triglycerides | 1991 |
[Comparison between lovastatin and gemfibrozil in treatment of primary hyperlipidemias].
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypertriglyceridemia; Lovastatin; Male; Middle Aged; Triglycerides | 1991 |
[Therapy of hypercholesterolemia and hypertriglyceridemia. Comparison of hypolipemic effects of lovastatin and gemfibrozil].
Topics: Aged; Apolipoproteins B; Cholesterol; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Phospholipids; Triglycerides | 1991 |
Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients.
Topics: Cholestyramine Resin; Colestipol; Food, Formulated; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Lovastatin; Nephrotic Syndrome; Probucol | 1991 |
Treatment of combined hyperlipidemia with lovastatin versus gemfibrozil: a comparison study.
Topics: Apolipoproteins B; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Lovastatin; Male; Middle Aged; Triglycerides | 1990 |
Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins.
Topics: Adult; Aged; Apolipoproteins; Bezafibrate; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin | 1990 |
Hydroxymethylglutaryl coenzyme A reductase inhibitors as monotherapy in the treatment of hypercholesterolemia.
Topics: Bezafibrate; Cholestyramine Resin; Double-Blind Method; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipids; Lovastatin; Probucol; Randomized Controlled Trials as Topic; Simvastatin | 1990 |
Comparison of the effects of lovastatin and gemfibrozil on lipids and glucose control in non-insulin-dependent diabetes mellitus.
Topics: Adult; Aged; Aged, 80 and over; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Randomized Controlled Trials as Topic; Triglycerides | 1990 |
Primary hypertriglyceridemia with borderline high cholesterol and elevated apolipoprotein B concentrations. Comparison of gemfibrozil vs lovastatin therapy.
Topics: Adult; Aged; Apolipoproteins B; Cholesterol; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged | 1990 |
[Simvastatin versus gemfibrozil in the treatment of primary hypercholesterolemia in hypertensive patients treated with hydrochlorothiazide].
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Female; Gemfibrozil; Humans; Hydrochlorothiazide; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1990 |
Management of primary mixed hyperlipidemia with lovastatin.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Drug Therapy, Combination; Gemfibrozil; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Triglycerides | 1990 |
Influence of lovastatin plus gemfibrozil on plasma lipids and lipoproteins in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Female; Gemfibrozil; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Triglycerides | 1989 |
Comparison of low-dose simvastatin and gemfibrozil in the treatment of elevated plasma cholesterol. A multicenter study. The Simvastatin Study Group.
Topics: Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Gemfibrozil; Humans; Lovastatin; Male; Middle Aged; Multicenter Studies as Topic; Random Allocation; Simvastatin | 1989 |
Comparison of lovastatin and gemfibrozil in normolipidemic patients with hypoalphalipoproteinemia.
Topics: Adult; Aged; Analysis of Variance; Apolipoproteins; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Gemfibrozil; Humans; Hypolipoproteinemias; Lipids; Lipoproteins, HDL; Lovastatin; Male; Middle Aged; Random Allocation; Triglycerides | 1989 |
Gemfibrozil alone and in combination with lovastatin for treatment of hypertriglyceridemia in NIDDM.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gemfibrozil; Humans; Hypertriglyceridemia; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged | 1989 |
Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study.
Topics: Adult; Double-Blind Method; Female; Finland; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Male; Multicenter Studies as Topic; Random Allocation | 1988 |
Combination drug therapy for familial combined hyperlipidemia.
Topics: Adult; Cholelithiasis; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pentanoic Acids; Polyamines; Random Allocation; Ultrasonography; Valerates | 1988 |
A randomized trial to assess effectiveness and cost in clinical practice: rationale and design of the Cholesterol Reduction Intervention Study (CRIS).
Topics: Adult; Aged; Cholesterol, LDL; Coronary Disease; Cost-Benefit Analysis; Costs and Cost Analysis; Follow-Up Studies; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Middle Aged; Niacin; Patient Selection; Prospective Studies; Risk Factors; Treatment Outcome | 1995 |
Changes in plasma lipid and apolipoprotein levels between heparin-induced extracorporeal low-density lipoprotein precipitation (HELP) treatments.
Topics: Adult; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Blood Component Removal; Chemical Precipitation; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Extracorporeal Circulation; Female; Gemfibrozil; Heparin; Humans; Hypercholesterolemia; Hyperlipidemias; Lipids; Lipoproteins, LDL; Lovastatin; Male | 1995 |
Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lipoprotein(a); Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Treatment Outcome; Triglycerides | 1995 |
Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.
Topics: Adult; Apolipoproteins B; Double-Blind Method; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipids; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Simvastatin; Triglycerides | 1995 |
A comparison between the effects of gemfibrozil and simvastatin on insulin sensitivity in patients with non-insulin-dependent diabetes mellitus and hyperlipoproteinemia.
Topics: Aged; Body Weight; Diabetes Complications; Diabetes Mellitus; Double-Blind Method; Female; Gemfibrozil; Glucose Tolerance Test; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Insulin; Lipoprotein Lipase; Lipoprotein(a); Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Simvastatin | 1995 |
[Clinical evaluation of simvastatin in the treatment of hyperlipidemia].
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1993 |
Effect of gemfibrozil and lovastatin on postprandial lipoprotein clearance in the hypoalphalipoproteinemia and hypertriglyceridemia syndrome.
Topics: Adult; Dietary Fats; Double-Blind Method; Eating; Fasting; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipoproteinemias; Lipids; Lipoprotein Lipase; Lipoproteins; Lipoproteins, HDL; Lovastatin; Male; Middle Aged; Syndrome; Triglycerides | 1993 |
[Comparison of the efficacy between simvastatin and gemfibrozil in primary hypercholesterolemia].
Topics: Adult; Aged; Double-Blind Method; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Simvastatin | 1993 |
The impact of a short course of three lipid lowering drugs on fat oxidation during exercise in healthy volunteers.
Topics: Adult; Anticholesteremic Agents; Blood Pressure; Energy Metabolism; Exercise; Exercise Test; Exercise Tolerance; Fatty Acids, Nonesterified; Gemfibrozil; Heart Rate; Humans; Hydroxymethylglutaryl CoA Reductases; Hypolipidemic Agents; Lovastatin; Male; Oxidation-Reduction; Oxygen Consumption; Pyrazines; Random Allocation; Simvastatin; Single-Blind Method | 1993 |
Comparison of the efficacy of simvastatin and standard fibrate therapy in the treatment of primary hypercholesterolemia and combined hyperlipidemia.
Topics: Anticholesteremic Agents; Bezafibrate; Cholesterol, LDL; Clofibric Acid; Fatty Acids, Volatile; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1995 |
[Multicenter comparative study on safety, tolerance, and effectiveness of lovastatin combined or not with cholestyramine, and gemfibrozil combined or not with cholestyramine in the treatment of primary hypercholesterolemia].
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholestyramine Resin; Double-Blind Method; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Triglycerides | 1996 |
Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.
Topics: Adult; Apolipoprotein C-III; Apolipoproteins B; Apolipoproteins C; Cholesterol; Double-Blind Method; Enzyme Inhibitors; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipoprotein(a); Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1996 |
Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study.
Topics: Adult; Aged; Cholesterol; Combined Modality Therapy; Cross-Over Studies; Diet, Fat-Restricted; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypertriglyceridemia; Hypolipidemic Agents; Kidney Failure, Chronic; Lovastatin; Male; Middle Aged; Peritoneal Dialysis, Continuous Ambulatory; Prospective Studies; Simvastatin; Triglycerides | 1996 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
A comparative study of the efficacy of simvastatin and gemfibrozil in combined hyperlipoproteinemia: prediction of response by baseline lipids, apo E genotype, lipoprotein(a) and insulin.
Topics: Anticholesteremic Agents; Apolipoproteins E; Cholesterol; Cross-Over Studies; Dietary Fats; Gemfibrozil; Genotype; Humans; Hyperlipidemia, Familial Combined; Hyperlipoproteinemias; Hypolipidemic Agents; Insulin; Lipids; Lipoprotein(a); Lipoproteins; Lovastatin; Predictive Value of Tests; Simvastatin; Triglycerides | 1997 |
Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol, LDL; Clofibric Acid; Drug Therapy, Combination; Female; Fibric Acids; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome | 1997 |
[Gemfibrozil reduces elevated lipoprotein (a) levels in hypercholesterolemic patients].
Topics: Analysis of Variance; Anticholesteremic Agents; Chi-Square Distribution; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipoprotein(a); Lovastatin; Male; Middle Aged | 1997 |
Lipoprotein composition and oxidative modification during therapy with gemfibrozil and lovastatin in patients with combined hyperlipidaemia.
Topics: Double-Blind Method; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipoproteins, LDL; Lipoproteins, VLDL; Lovastatin; Oxidation-Reduction; Placebos | 1998 |
Randomized crossover study of gemfibrozil versus lovastatin in familial combined hyperlipidemia: additive effects of combination treatment on lipid regulation.
Topics: Adult; Aged; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Hypolipidemic Agents; Lipid Metabolism; Lovastatin; Male; Middle Aged | 1999 |
Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate.
Topics: Adult; Area Under Curve; Bezafibrate; Cross-Over Studies; Drug Interactions; Female; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male | 2001 |
Effects of hypolipidemic treatment on serum markers of vascular inflammation in dyslipidemic men.
Topics: Adult; Bezafibrate; Biomarkers; Chemokine CCL2; E-Selectin; Gemfibrozil; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Hypolipidemic Agents; Inflammation Mediators; Lovastatin; Male; Middle Aged; Simvastatin; Vascular Cell Adhesion Molecule-1 | 2003 |
65 other study(ies) available for gemfibrozil and lovastatin
| Article | Year |
|---|---|
Discovery of 1-(4-fluorophenyl)-(3R)-[3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4 -hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption.
Topics: Animals; Anticholesteremic Agents; Azetidines; Cholesterol; Cricetinae; Drug Design; Ezetimibe; Liver; Structure-Activity Relationship | 1998 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
A retrospective review of the use of lipid-lowering agents in combination, specifically, gemfibrozil and lovastatin.
Topics: Aged; Alanine Transaminase; Cholestyramine Resin; Colestipol; Creatine Kinase; Drug Interactions; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Lipids; Lovastatin; Male; Middle Aged; Niacin; Retrospective Studies | 1992 |
Lovastatin/gemfibrozil myopathy: a clinical, histochemical, and ultrastructural study.
Topics: Drug Therapy, Combination; Female; Gemfibrozil; Humans; Lovastatin; Microscopy, Electron; Middle Aged; Muscles; Muscular Diseases | 1992 |
Efficacy and cost-effectiveness of simvastatin and gemfibrozil in the treatment of hyperlipidaemia.
Topics: Cost-Benefit Analysis; Drug Evaluation; Female; Follow-Up Studies; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Simvastatin | 1992 |
Effects of lovastatin and gemfibrozil on high-density lipoprotein subfraction density and composition in patients with familial hypercholesterolemia.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein A-II; Centrifugation, Density Gradient; Chemical Fractionation; Cholesterol Esters; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lovastatin; Male; Middle Aged; Triglycerides | 1992 |
Gemfibrozil-lovastatin therapy for primary hyperlipoproteinemias.
Topics: Adult; Aged; Analysis of Variance; Cholesterol; Combined Modality Therapy; Creatine Kinase; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipoproteinemias; Liver Function Tests; Lovastatin; Male; Middle Aged; Myositis; Retrospective Studies; Triglycerides | 1992 |
Choice of cholesterol-lowering drugs.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Clofibrate; Colestipol; Fish Oils; Gemfibrozil; Humans; Lovastatin; Neomycin; Niacin; Probucol | 1991 |
[Myopathy during treatment with fibrates and lovastatin].
Topics: Aged; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Lovastatin; Male; Middle Aged; Myositis | 1991 |
Low density lipoprotein density and composition in hypercholesterolaemic men treated with HMG CoA reductase inhibitors and gemfibrozil.
Topics: Adult; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Simvastatin | 1991 |
Lovastatin and gemfibrozil in the treatment of type 2a and type 2b hyperlipoproteinemia.
Topics: Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lovastatin | 1991 |
Cholesterol-lowering agent myopathy (CLAM).
Topics: Aged; Anticholesteremic Agents; Female; Gemfibrozil; Humans; Lovastatin; Muscular Diseases | 1991 |
Treatment choices for hypertriglyceridemia.
Topics: Gemfibrozil; Humans; Hypertriglyceridemia; Lovastatin | 1990 |
Myopathy and rhabdomyolysis with lovastatin taken with gemfibrozil.
Topics: Adolescent; Creatine Kinase; Drug Synergism; Drug Therapy, Combination; Gemfibrozil; Humans; Isoenzymes; Lovastatin; Male; Middle Aged; Muscular Diseases; Rhabdomyolysis | 1990 |
Rhabdomyolysis and acute renal failure induced by combination lovastatin and gemfibrozil therapy.
Topics: Acute Kidney Injury; Biological Assay; Drug Interactions; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lovastatin; Male; Middle Aged; Rhabdomyolysis | 1990 |
[A case of familial hypercholesterolemia with therapeutic difficulties].
Topics: Adult; Bezafibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Lovastatin; Male; Nicotinic Acids; Simvastatin | 1990 |
Safety and efficacy of combined gemfibrozil-lovastatin therapy for primary dyslipoproteinemias.
Topics: Adult; Aged; Arteriosclerosis; Cholesterol; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Lipid Metabolism, Inborn Errors; Lipids; Lipoproteins; Lovastatin; Male; Middle Aged | 1990 |
Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy.
Topics: Acute Kidney Injury; Adult; Aged; Creatine Kinase; Drug Interactions; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Middle Aged; Muscular Diseases; Rhabdomyolysis | 1990 |
Lovastatin-induced acute rhabdomyolysis.
Topics: Acute Disease; Age Factors; Aged; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Kidney Failure, Chronic; Lovastatin; Muscles; Rhabdomyolysis | 1990 |
The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis.
Topics: Aged; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Lovastatin; Myositis; Rhabdomyolysis | 1989 |
Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.
Topics: Adult; Apolipoproteins B; Cholesterol; Cholesterol, LDL; Cholesterol, VLDL; Female; Gemfibrozil; Humans; Hyperlipoproteinemia Type III; Kinetics; Lipoproteins, VLDL; Lovastatin; Male; Middle Aged; Pentanoic Acids; Triglycerides | 1988 |
[Therapeutic possibilities of a newly registered lipid suppressor].
Topics: Anticholesteremic Agents; Colestipol; Gemfibrozil; Humans; Lovastatin; Simvastatin | 1988 |
Current and new therapy for hypercholesterolemia.
Topics: Anticholesteremic Agents; Colestipol; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Niacin; Probucol | 1988 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Drug Tolerance; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Lovastatin; Male; Middle Aged; Naphthalenes; Neomycin; Niacin; Pentanoic Acids; Probucol; Simvastatin; Triglycerides | 1987 |
Some comparative effects of gemfibrozil, clofibrate, bezafibrate, cholestyramine and compactin on sterol metabolism in rats.
Topics: Animals; Anticholesteremic Agents; Bezafibrate; Caprylates; Carbon Radioisotopes; Cholesterol; Cholesterol, Dietary; Cholestyramine Resin; Clofibrate; Gemfibrozil; Hypolipidemic Agents; Liver; Lovastatin; Male; Mevalonic Acid; Naphthalenes; Pentanoic Acids; Rats; Rats, Inbred F344; Sterols; Valerates | 1983 |
HMG-CoA reductase inhibitors, gemfibrozil, and myopathy.
Topics: Drug Combinations; Drug Interactions; Follow-Up Studies; Gemfibrozil; Humans; Lovastatin; Muscular Diseases; Pravastatin | 1995 |
Warfarin therapy.
Topics: Drug Synergism; Gemfibrozil; Humans; Lovastatin; Warfarin | 1995 |
Postprandial apolipoprotein B100 and B48 metabolism in familial combined hyperlipidaemia before and after reduction of fasting plasma triglycerides.
Topics: Adult; Aged; Apolipoprotein B-100; Apolipoprotein B-48; Apolipoproteins B; Child; Cholesterol; Drug Therapy, Combination; Fasting; Female; Gemfibrozil; Humans; Hyperlipidemia, Familial Combined; Lovastatin; Male; Middle Aged; Simvastatin; Triglycerides | 1994 |
Fish oil (omega-3 fatty acids) in treatment of hypertriglyceridemia. A practical approach for the primary care physician.
Topics: Aged; Clofibrate; Drug Therapy, Combination; Fatty Acids, Omega-3; Female; Gemfibrozil; Humans; Hypertriglyceridemia; Lipids; Lovastatin; Niacin; Primary Health Care | 1994 |
Rhabdomyolysis and acute renal failure in a heart transplant recipient treated with hypolipemiants.
Topics: Acute Kidney Injury; Gemfibrozil; Heart Transplantation; Humans; Hyperlipidemias; Leprostatic Agents; Lovastatin; Male; Middle Aged; Rhabdomyolysis | 1994 |
Lovastatin and myopathy.
Topics: Drug Synergism; Gemfibrozil; Humans; Lovastatin; Muscular Diseases; Pravastatin | 1994 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Rhabdomyolysis and renal failure secondary to combination therapy of hyperlipidemia with lovastatin and gemfibozil.
Topics: Acute Kidney Injury; Drug Therapy, Combination; Gemfibrozil; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Rhabdomyolysis | 1993 |
Lipoprotein responses to treatment with lovastatin, gemfibrozil, and nicotinic acid in normolipidemic patients with hypoalphalipoproteinemia.
Topics: Gemfibrozil; Humans; Hypolipoproteinemias; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Niacin | 1994 |
Gemfibrozil-lovastatin-associated myalgia.
Topics: Drug Therapy, Combination; Gemfibrozil; Humans; Lovastatin; Muscular Diseases | 1993 |
Treatment of hyperlipidemia in heart transplant recipients with gemfibrozil +/- lovastatin.
Topics: Female; Gemfibrozil; Heart Transplantation; Humans; Hyperlipidemias; Lovastatin; Male; Middle Aged; Retrospective Studies; Treatment Outcome | 1993 |
Pancreatitis and rhabdomyolysis associated with lovastatin-gemfibrozil therapy.
Topics: Acute Disease; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Pancreatic Pseudocyst; Pancreatitis; Rhabdomyolysis | 1995 |
Carcinogenicity of lipid-lowering drugs.
Topics: Acyl Coenzyme A; Gemfibrozil; Humans; Hypolipidemic Agents; Liver; Liver Neoplasms; Lovastatin | 1996 |
Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Cyclosporine; Drug Interactions; Fenofibrate; Gemfibrozil; Heart Transplantation; Humans; Hypolipidemic Agents; Immunosuppressive Agents; Lovastatin; Probucol; Simvastatin | 1996 |
Reasons for stopping drugs are monitored in New Zealand.
Topics: Adverse Drug Reaction Reporting Systems; Bezafibrate; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; New Zealand; Product Surveillance, Postmarketing; Simvastatin | 1996 |
Inhibition of acyl-CoA: cholesterol acyltransferase decreases apolipoprotein B-100-containing lipoprotein secretion from HepG2 cells.
Topics: Albumins; Aniline Compounds; Apolipoprotein B-100; Apolipoproteins B; Enzyme Inhibitors; Gemfibrozil; Humans; Hydroxycholesterols; Hypolipidemic Agents; Lipids; Liver; Lovastatin; Phenylurea Compounds; Sterol O-Acyltransferase; Tumor Cells, Cultured | 1996 |
Myopathy associated with lipid lowering therapy in patients with previously undiagnosed or undertreated hypothyroidism.
Topics: Aged; Anticholesteremic Agents; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Hypothyroidism; Indoles; Lovastatin; Male; Middle Aged; Neuromuscular Diseases; Simvastatin; Thyroxine | 1996 |
Possible increased risk of rhabdomyolysis during concomitant use of simvastatin and gemfibrozil.
Topics: Drug Synergism; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Rhabdomyolysis; Risk; Simvastatin | 1996 |
Effects of initial BMI and on-treatment weight change on the lipid-lowering efficacy of fibrates.
Topics: Body Mass Index; Clofibric Acid; Female; Fenofibrate; Fibric Acids; Gemfibrozil; Humans; Hypercholesterolemia; Hypolipidemic Agents; Lipids; Lovastatin; Male; Middle Aged; Prospective Studies; Sex Factors; Simvastatin; Weight Loss | 1997 |
The Scandinavian Simvastatin Survival Study (4S) subgroup analysis of diabetic subjects: implications for the prevention of coronary heart disease.
Topics: Anticholesteremic Agents; Cholesterol, HDL; Coronary Disease; Diabetic Angiopathies; Gemfibrozil; Humans; Hypolipidemic Agents; Lovastatin; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; Risk Factors; Scandinavian and Nordic Countries; Simvastatin; Survival Rate; Triglycerides | 1997 |
Rhabdomyolysis associated with simvastatin-gemfibrozil therapy.
Topics: Anticholesteremic Agents; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Middle Aged; Muscular Diseases; Rhabdomyolysis; Simvastatin | 1997 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Female; Follow-Up Studies; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemias; Hypertriglyceridemia; Hypolipidemic Agents; Immunosuppressive Agents; Lipids; Lipoproteins, HDL; Lipoproteins, LDL; Lovastatin; Lung Transplantation; Male; Middle Aged; Myocardial Ischemia; Probucol; Radionuclide Angiography; Retrospective Studies; Triglycerides; Ventricular Dysfunction, Left; Ventricular Function, Left | 1997 |
Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins E; Data Interpretation, Statistical; Drug Interactions; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Lovastatin; Male; Middle Aged; Phenotype; Polymorphism, Genetic | 1998 |
Apolipoprotein E*3-Leiden transgenic mice as a test model for hypolipidaemic drugs.
Topics: Animals; Anticoagulants; Apolipoprotein E3; Apolipoproteins E; Cholesterol; Drug Evaluation, Preclinical; Gemfibrozil; Heparin; Hypolipidemic Agents; Lactones; Lipids; Lipoprotein Lipase; Liver; Lovastatin; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; RNA, Messenger; Triglycerides | 1998 |
Effects of lovastatin and gemfibrozil in subjects with high ratios of total cholesterol to high-density lipoprotein cholesterol.
Topics: Adult; Aged; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Insulin; Leptin; Lovastatin; Male; Middle Aged; Obesity; Proteins | 1999 |
Long-term safety and efficacy of combination gemfibrozil and HMG-CoA reductase inhibitors for the treatment of mixed lipid disorders.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Indoles; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Prospective Studies; Pyrroles; Simvastatin; Time Factors; Treatment Outcome | 1999 |
Rhabdomyolysis associated with the combined use of hydroxymethylglutaryl-coenzyme A reductase inhibitors with gemfibrozil and macrolide antibiotics.
Topics: Adult; Aged; Anti-Bacterial Agents; Anticholesteremic Agents; Clarithromycin; Drug Therapy, Combination; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Rhabdomyolysis | 1999 |
Effect of dietary lipid-lowering drugs upon plasma lipids and egg yolk cholesterol levels of laying hens.
Topics: Animals; Anticholesteremic Agents; Chickens; Cholesterol; Dietary Supplements; Egg Yolk; Female; Gemfibrozil; Lipids; Lovastatin; Probucol; Triglycerides | 1999 |
Cholesterol-lowering drugs. Some drugs with demonstrated efficacy but different benefits in primary and secondary prevention.
Topics: Anticholesteremic Agents; Bezafibrate; Cholestyramine Resin; Clinical Trials as Topic; Clofibrate; Female; Gemfibrozil; Humans; Hypercholesterolemia; Lovastatin; Male; Myocardial Infarction; Pravastatin; Treatment Outcome | 1999 |
Therapy and clinical trials.
Topics: Cholesterol, HDL; Clinical Trials as Topic; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Neoplasms; Risk Assessment; Simvastatin; Venous Thrombosis | 2002 |
Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.
Topics: Adult; Antipsychotic Agents; Atorvastatin; Cholesterol; Clozapine; Female; Fenofibrate; Gemfibrozil; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Psychotic Disorders; Pyrroles; Retrospective Studies; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
Establishment and characterization of a mouse model of rhabdomyolysis by coadministration of statin and fibrate.
Topics: Animals; Caspase 3; Caspase 7; Disease Models, Animal; Drug Interactions; Female; Fibric Acids; Gemfibrozil; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Mice; Mice, Inbred C57BL; Muscle, Skeletal; Real-Time Polymerase Chain Reaction; Rhabdomyolysis | 2019 |